SCOPUS 정보 검색 플랫폼

Journal of Orthopaedic Science

Volumn 13, Issue 5, 2008, Pages 438-441

Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment

(6) Iba, Kousuke a Takada, Junichi b Hatakeyama, Naoko a Ozasa, Yasuhiro a Wada, Takuro a Yamashita, Toshihiko a

a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE (Japan)

b Chitose City Hospital (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; FEMALE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; OUTPATIENT; PRIMARY OSTEOPOROSIS; PROTEIN URINE LEVEL; URINALYSIS;

EID: 52649109464 PISSN: 09492658 EISSN: None Source Type: Journal
DOI: 10.1007/s00776-008-1265-z Document Type: Article

Times cited : (14)

References (10)

1
- 0032583492
- Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
- S.R. Cummings D.M. Black D.E. Thompson W.B. Applegate E. Barrett-Connor T.A. Musliner 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082
- (1998) JAMA , vol.280 , pp. 2077-2082
- Cummings, S.R.¹ Black, D.M.² Thompson, D.E.³ Applegate, W.B.⁴ Barrett-Connor, E.⁵ Musliner, T.A.⁶

2
- 0034530951
- Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group
- D.M. Black D.E. Thompson D.C. Bauer K. Ensrud T. Musliner M.C. Hochberg 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 4118 4124
- (2000) J Clin Endocrinol Metab , vol.85 , pp. 4118-4124
- Black, D.M.¹ Thompson, D.E.² Bauer, D.C.³ Ensrud, K.⁴ Musliner, T.⁵ Hochberg, M.C.⁶

3
- 0033552255
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial: Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
- S.T. Harris N.B. Watts H.K. Genant C.D. McKeever T. Hangartner M. Keller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial: Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352
- (1999) JAMA , vol.282 , pp. 1344-1352
- Harris, S.T.¹ Watts, N.B.² Genant, H.K.³ McKeever, C.D.⁴ Hangartner, T.⁵ Keller, M.⁶

4
- 12944291524
- Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
- J.Y. Reginster H.W. Minne O.H. Sorensen M. Hooper C. Roux M.L. Brandi 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91
- (2000) Osteoporos Int , vol.11 , pp. 83-91
- Reginster, J.Y.¹ Minne, H.W.² Sorensen, O.H.³ Hooper, M.⁴ Roux, C.⁵ Brandi, M.L.⁶

5
- 33847271658
- Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate
- J. Takada K. Iba K. Imoto T. Yamashita 2007 Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate J Bone Miner Metab 25 142 146
- (2007) J Bone Miner Metab , vol.25 , pp. 142-146
- Takada, J.¹ Iba, K.² Imoto, K.³ Yamashita, T.⁴

6
- 12144289279
- Ten years' experience with alendronate for osteoporosis in postmenopausal women
- H.G. Bone D. Hosking J.P. Devogelaer J.R. Tucci R.D. Emkey R.P. Tonino 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 1199
- (2004) N Engl J Med , vol.350 , pp. 1189-1199
- Bone, H.G.¹ Hosking, D.² Devogelaer, J.P.³ Tucci, J.R.⁴ Emkey, R.D.⁵ Tonino, R.P.⁶

7
- 15944413442
- Severely suppressed bone turnover: A potential complication of alendronate therapy
- C.V. Odvina J.E. Zerwekh D.S. Rao N. Maalouf F.A. Gottschalk C.Y. Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301
- (2005) J Clin Endocrinol Metab , vol.90 , pp. 1294-1301
- Odvina, C.V.¹ Zerwekh, J.E.² Rao, D.S.³ Maalouf, N.⁴ Gottschalk, F.A.⁵ Pak, C.Y.⁶

8
- 34548027241
- Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy
- K. Imai S. Yamamoto Y. Anamizu T. Horiuchi 2007 Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy J Bone Miner Metab 25 333 336
- (2007) J Bone Miner Metab , vol.25 , pp. 333-336
- Imai, K.¹ Yamamoto, S.² Anamizu, Y.³ Horiuchi, T.⁴

9
- 20944436377
- Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)
- Y. Nishizawa T. Nakamura H. Ohta K. Kushida I. Gorai M. Shiraki 2005 Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004) J Bone Miner Metab 23 97 104
- (2005) J Bone Miner Metab , vol.23 , pp. 97-104
- Nishizawa, Y.¹ Nakamura, T.² Ohta, H.³ Kushida, K.⁴ Gorai, I.⁵ Shiraki, M.⁶

10
- 15944429695
- Long-term safety of bisphosphonates
- S.M. Ott 2005 Long-term safety of bisphosphonates J Clin Endocrinol Metab 90 1897 1899
- (2005) J Clin Endocrinol Metab , vol.90 , pp. 1897-1899
- Ott, S.M.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.